Compare BridgeBio Pharma Inc (BBIO) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Exxon Mobil Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Exxon Mobil Corporation trades at $159.78 (market cap $634.34B). The key difference: Exxon Mobil Corporation is far larger — about 38.2× BridgeBio Pharma Inc's market cap, and Exxon Mobil Corporation pays a 2.69% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | XOM | |
|---|---|---|
Market Cap | $16.61B | $634.34B |
Sector | Health | Energy |
52-Week High | $90.17 | $171.52 |
52-Week Low | $47.29 | $106.13 |
Enterprise Value | $18.16B | $673.57B |
Dividend Yield | — | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
ExxonMobil (XOM) trades at $159.80, up 4.49% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q1 2026 but missing in Q2, while revenue and net income have trended lower since 2022. The company maintains robust cash flow from operations and a solid balance sheet with low debt levels, supporting consistent dividends.
Outlook remains positive due to high oil price forecasts and Permian Basin growth, but risks include declining profitability margins and geopolitical volatility. The stock offers value near the consensus price target of $163.71, with institutional sentiment leaning bullish amid energy sector tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
